Efficacy of Grow Out Oils Clinical Aromatherapy Antiviral Hydrosol Sprays against SARS-CoV-2: A Clinical Case Study

Infectious diseases, particularly those caused by viruses, continue to be a major public health concern globally. COVID-19, caused by the novel coronavirus SARS-CoV-2, has led to significant morbidity and mortality [1]. The clinical manifestations of COVID-19 can vary widely, from mild respiratory symptoms to severe pneumonia and long-term sequelae. In light of the ongoing pandemic, there is an urgent need for effective disinfection strategies that are both safe and effective in mitigating the spread of the virus [2-4].

To investigate the vicidal efficacy of Grow Out Oils Clinical Aromatherapy Antiviral Hydrosol Sprays, specifically targeting their ability to deactivate SARS-CoV-2 and other coronaviruses in both airborne and surface environments [5-8].

A series of in vitro experiments were conducted to evaluate the vicidal properties of the Grow Out Oils Clinical Antiviral Hydrosol Sprays [9-14]. The primary active ingredient, Cinnamaldehyde, along with other synergistic constituents derived from cinnamon blends, were analyzed for their ability to disrupt the viral lipid bilayer [15-19].

Formulation: The hydrosol sprays were formulated using proprietary high ionic salt technology, designed to generate micro-crystals capable of inactivating viral particles upon contact.

Concentration: The sprays were tested at a concentration of 500 ppm.

Testing Procedure: The vicidal activity was assessed by exposing coronaviruses to the hydrofoil sprays for one minute, measuring the reduction in viral particles.

The results indicated that the Grow Out Oils Clinical Antiviral Hydrosol Sprays effectively inactivated coronaviruses, including variants with a size of 0.5 microns, in under one minute of exposure.

The inactivation rate demonstrated by the sprays supports their potential use as disinfection tools in clinical settings, particularly where the risk of transmission is heightened.

Unlike conventional disinfectants, which often contain harmful chemicals with potential health risks (including carcinogenicity and respiratory complications), the Grow Out Oils Sprays are 100% all-natural and non-toxic [20-24]. This safety profile is crucial for their application in environments such as hospitals and clinics, where patient safety is paramount [25-29].

This study was conducted under the guidance of Dr. Lane Rolling, M.D., an esteemed infectious disease expert, trauma surgeon, and member of the COVID-19 Health Care Task Force of the Congressional Black Caucus. Dr. Rolling holds extensive experience in virology, epidemiology, and microbiology, making his involvement pivotal in validating the findings of this research.

Dr. Lane Rolling, M.D.: A well-respected infectious disease doctor, Dr. Rolling has dedicated his career to understanding and combating infectious diseases. His extensive background in virology and epidemiology has been instrumental in the design and evaluation of this study, ensuring that the methodologies employed meet rigorous scientific standards. Dr. Rolling also was a BioSafety Expert in the Coronavirus that causes Covid-19 disease. This was a one-year clinical case study that completed by Dr. Rolling in (2021).

Shanna Bynes Bradford: As the Master Aromatherapist Formulator Chemist behind the Grow Out Oils Clinical Aromatherapy Antiviral Hydrosol Sprays, Shanna Bynes Bradford brings a wealth of knowledge and expertise to the formulation process and she specialize in Trichology and dermal absorption of active/herbal ingredient for the past 26 plus years. She is a Licensed Medical Aesthetician and an Ambassador/graduate of The American College of Healthcare Science, Certified Reflexologist, and Aesthetics Professional Makeup Artist (MUA), specializing in creating holistic and effective aromatherapeutic products. Her commitment to using all-natural ingredients aligns with the growing demand for safe and environmentally friendly disinfection solutions.

The findings advocate for the integration of innovative, safe, and effective disinfection strategies into standard practice in healthcare settings. Given the continuous challenges posed by COVID-19 and other infectious diseases, the Grow Out Oils Clinical Aromatherapy Antiviral Hydrosol Sprays provide a viable alternative to traditional chemical disinfectants. Their rapid action and non-toxic formulation may significantly enhance infection control measures, ultimately improve patient safety and reduce healthcare-associated infections.

This clinical case study presents compelling evidence for the efficacy of Grow Out Oils Clinical Aromatherapy Antiviral Hydrosol Sprays in inactivating SARS-CoV-2 and other coronaviruses. By offering a safe and effective natural disinfection solution, these sprays may play a crucial role in the ongoing efforts to control the spread of infectious diseases in clinical environments.

1. Block MS and Rowan BG (2020) Hypochlorous acid: a review. Journal of Oral and Maxillofacial Surgery. 78: 1461-1466.
2. Sorroche MG, López IR, García-Delpech S and Del Castillo JB (2022) Hypochlorous acid as an antiseptic in the care of patients with suspected COVID-19 infection. Archivos de la Sociedad Española de Oftalmología (English Edition) 97: 77-80.
3. Hypochlorous Acid Kills COVID-19 – Effective Prevention and Control. Available at: Aqualution.
4. Artika IM and Ma'roef CN (2017) Laboratory biosafety for handling emerging viruses. Asian Pacific journal of tropical biomedicine 7: 483-491.
5. Bin SY, Heo JY, Song MS, Lee J, Kim EH, et al. (2016) Environmental contamination and viral shedding in MERS patients during MERS-CoV outbreak in South Korea. Clinical infectious diseases 62: 755-760.
6. Chander Y, Johnson T, Goyal SM and Russell RJ (2012) Antiviral activity of Ecasol against feline calicivirus, a surrogate of human norovirus. Journal of Infection and Public Health 5: 420-424.
7. Cho SY, Kang JM, Ha YE, Park GE, Lee JY, et al. (2016) MERS-CoV outbreak following a single patient exposure in an emergency room in South Korea: an epidemiological outbreak study. The Lancet. 388: 994-1001.
8. Chowell G, Castillo-Chavez C, Fenimore PW, Kribs-Zaleta CM, Arriola L, et al. (2004) Model parameters and outbreak control for SARS. Emerging infectious diseases 10: 1258.
9. Clark J, Barrett SP, Rogers M and Stapleton R (2006) Efficacy of super-oxidized water fogging in environmental decontamination. Journal of Hospital Infection 64: 386-390.
10. Dellanno C, Vega Q and Boesenberg D (2009) The antiviral action of common household disinfectants and antiseptics against murine hepatitis virus, a potential surrogate for SARS coronavirus. American Journal of Infection Control 37: 649-652.
11. Duan Shu Ming DS, Zhao Xin Sheng ZX, Wen Rui Fu WR, Huang Jing Jing HJ, Pi Guo Hua PG, et al. Stability of SARS coronavirus in human specimens and environment and its sensitivity to heating and UV irradiation.
12. Hudson JB, Sharma M and Petric M (2007) Inactivation of Norovirus by ozone gas in conditions relevant to healthcare. Journal of Hospital Infection 66: 40-45.
13. Hui DS, Azhar EI, Kim YJ, Memish ZA, Oh MD, et al. (2018) Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission. The Lancet Infectious Diseases 18: 217-227.
14. Jones KE, Patel NG, Levy MA, Storeygard A, Balk D, et al. (2008) Global trends in emerging infectious diseases. Nature 451: 990-993.
15. Knotzer S, Kindermann J, Modrof J and Kreil TR (2015) Measuring the effectiveness of gaseous virus disinfectants. Biologicals 43: 519-523.
16. Morino H, Fukuda T, Miura T, Lee C, Shibata T, et al. (2009) Inactivation of feline calicivirus, a norovirus surrogate, by chlorine dioxide gas. Biocontrol science 14: 147-153.
17. Purohit A, Kopferschmitt-Kubler MC, Moreau C, Popin E, Blaumeiser M, et al. (2000) Quaternary ammonium compounds and occupational asthma. International archives of occupational and environmental health 73:423-427.
18. Rabenau H, Kampf G, Cinatl J, Doerr HW (2005) Efficacy of various disinfectants against SARS coronavirus. Journal of Hospital Infection 61: 107-111.
19. Rabenau HF, Cinatl J, Morgenstern B, Bauer G, Preiser W, et al. (2005) Stability and inactivation of SARS coronavirus. Medical microbiology and immunology 194: 1-6.
20. Radun D, Niedrig M, Ammon A, and Stark K (2003) SARS: retrospective cohort study among German guests of the hotel “M”, Hong Kong. Eurosurveillance 8: 228–230.
21. Ravis SM, Shaffer MP, Shaffer CL, Dehkhaghani S and Belsito DV (2003) Glutaraldehyde-induced and formaldehyde-induced allergic contact dermatitis among dental hygienists and assistants. The Journal of the American Dental Association 134: 1072-1078.
22. Rutala WA and Weber DJ (2014) Selection of the ideal disinfectant. Infection Control & Hospital Epidemiology 35: 855-865.
23. Song JY, Cheong HJ, Choi MJ, Jeon JH, Kang SH, et al. (2015) Viral shedding and environmental cleaning in Middle East respiratory syndrome coronavirus infection. Infection & Chemotherapy 47: 252.
24. Spaulding EH (1972) Chemical disinfection and antisepsis in the hospital. J Hosp Res 9: 7-31.
25. Whitehead K and McCue KA (2010) Virucidal efficacy of disinfectant actives against feline calicivirus, a surrogate for norovirus, in a short contact time. American journal of infection control 38: 26-30.
26. Atkinson J, Editor. Natural ventilation for infection control in health-care settings.
27. World Health Organization (2019) Infection prevention and control during health care for probable or confirmed cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection: interim guidance.
28. Wigginton KR, Pecson BM, Sigstam T, Bosshard F and Kohn T (2012) Virus inactivation mechanisms: impact of disinfectants on virus function and structural integrity. Environmental science & technology 46: 12069-12078.
29. Zhao S, Lin Q, Ran J, Musa SS, Yang G, et al. (2019) Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the outbreak. International journal of infectious diseases 92: 214-217.